Video: Clinical Trial: BMS-906024 for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Runtime
02:00

Dan Douer, Leader of the Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering, describes a phase I trial of intravenous BMS-906024 for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma. The experimental agent inhibits a signaling pathway called Notch, which helps cancer cells grow and survive. It also inhibits the development of blood vessels that cancers need to grow and spread.